<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=11611&amp;modal=1&amp;valnames=arms&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="418503" class="table-">
                
                <td>July 7, 2022, 1:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Immunotherapy; Active;Administration; Sublingual;Administration; Intranasal;Nasal Sprays;CIGB 2020;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.Group II (control): Treatment established in the national action protocol for COVID-19.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group II (control): Treatment established in the national action protocol for COVID-19.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;nasal spray: on days 1 and 7 and sublingual&quot;, &quot;treatment_id&quot;: 285, &quot;treatment_name&quot;: &quot;Cigb 2020&quot;, &quot;treatment_type&quot;: &quot;Non covid vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Non covid vaccine&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 2188, &quot;treatment_name&quot;: &quot;Standard of care&quot;, &quot;treatment_type&quot;: &quot;Standard of care&quot;, &quot;pharmacological_treatment&quot;: &quot;Standard of care&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="415207" class="table-">
                
                <td>June 23, 2022, 2 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.Group II (control): Treatment established in the national action protocol for COVID-19.;Immunotherapy; Active;Administration; Sublingual;Administration; Intranasal;Nasal Sprays;CIGB 2020&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group II (control): Treatment established in the national action protocol for COVID-19.;Immunotherapy; Active;Administration; Sublingual;Administration; Intranasal;Nasal Sprays;CIGB 2020&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 285, &quot;treatment_name&quot;: &quot;Cigb 2020&quot;, &quot;treatment_type&quot;: &quot;Non covid vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Non covid vaccine&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 2188, &quot;treatment_name&quot;: &quot;Standard of care&quot;, &quot;treatment_type&quot;: &quot;Standard of care&quot;, &quot;pharmacological_treatment&quot;: &quot;Standard of care&quot;}, {&quot;arm_notes&quot;: &quot;no third arm to delete&quot;, &quot;treatment_id&quot;: 2188, &quot;treatment_name&quot;: &quot;Standard of care&quot;, &quot;treatment_type&quot;: &quot;Standard of care&quot;, &quot;pharmacological_treatment&quot;: &quot;Standard of care&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="414297" class="table-">
                
                <td>June 17, 2022, 12:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Immunotherapy; Active;Administration; Sublingual;Administration; Intranasal;Nasal Sprays;CIGB 2020;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.Group II (control): Treatment established in the national action protocol for COVID-19.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group II (control): Treatment established in the national action protocol for COVID-19.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 285, &quot;treatment_name&quot;: &quot;Cigb 2020&quot;, &quot;treatment_type&quot;: &quot;Non covid vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Non covid vaccine&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 2187, &quot;treatment_name&quot;: &quot;Placebo&quot;, &quot;treatment_type&quot;: &quot;Placebo&quot;, &quot;pharmacological_treatment&quot;: &quot;Placebo&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="296101" class="table-">
                
                <td>March 17, 2022, 5 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.Group II (control): Treatment established in the national action protocol for COVID-19.;Immunotherapy; Active;Administration; Sublingual;Administration; Intranasal;Nasal Sprays;CIGB 2020&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group II (control): Treatment established in the national action protocol for COVID-19.;Immunotherapy; Active;Administration; Sublingual;Administration; Intranasal;Nasal Sprays;CIGB 2020&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 285, &quot;treatment_name&quot;: &quot;Cigb 2020&quot;, &quot;treatment_type&quot;: &quot;Non covid vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Non covid vaccine&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 2188, &quot;treatment_name&quot;: &quot;Standard of care&quot;, &quot;treatment_type&quot;: &quot;Standard of care&quot;, &quot;pharmacological_treatment&quot;: &quot;Standard of care&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="295885" class="table-">
                
                <td>March 11, 2022, 3:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Immunotherapy; Active;CIGB 2020;Nasal Sprays;Administration; Intranasal;Administration; Sublingual;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.Group II (control): Treatment established in the national action protocol for COVID-19.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group II (control): Treatment established in the national action protocol for COVID-19.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;(100 \u00b5g nasal spray;2;days1-7)+(100 \u00b5g/1ML sublingual daily)&quot;, &quot;treatment_id&quot;: 285, &quot;treatment_name&quot;: &quot;Cigb 2020&quot;, &quot;treatment_type&quot;: &quot;Non covid vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Non covid vaccine&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 2188, &quot;treatment_name&quot;: &quot;Standard of care&quot;, &quot;treatment_type&quot;: &quot;Standard of care&quot;, &quot;pharmacological_treatment&quot;: &quot;Standard of care&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="251791" class="table-">
                
                <td>May 27, 2021, 12:45 a.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.Group II (control): Treatment established in the national action protocol for COVID-19.;Nasal Sprays;Immunotherapy; Active;Administration; Sublingual;Administration; Intranasal;CIGB 2020&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group II (control): Treatment established in the national action protocol for COVID-19.;Nasal Sprays;Immunotherapy; Active;Administration; Sublingual;Administration; Intranasal;CIGB 2020&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="244931" class="table-">
                
                <td>March 26, 2021, 2:21 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 ug HBsAg + 100 ug HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19. Group II (control): Treatment established in the national action protocol for COVID-19.;Immunotherapy; Active;CIGB 2020&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 ug HBsAg + 100 ug HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group II (control): Treatment established in the national action protocol for COVID-19.;Immunotherapy; Active;CIGB 2020&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
July 7, 2022, 1:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Immunotherapy; Active;Administration; Sublingual;Administration; Intranasal;Nasal Sprays;CIGB 2020;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.Group II (control): Treatment established in the national action protocol for COVID-19.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (control): Treatment established in the national action protocol for COVID-19.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "nasal spray: on days 1 and 7 and sublingual", "treatment_id": 285, "treatment_name": "Cigb 2020", "treatment_type": "Non covid vaccine", "pharmacological_treatment": "Non covid vaccine"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
June 23, 2022, 2 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.Group II (control): Treatment established in the national action protocol for COVID-19.;Immunotherapy; Active;Administration; Sublingual;Administration; Intranasal;Nasal Sprays;CIGB 2020", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (control): Treatment established in the national action protocol for COVID-19.;Immunotherapy; Active;Administration; Sublingual;Administration; Intranasal;Nasal Sprays;CIGB 2020", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 285, "treatment_name": "Cigb 2020", "treatment_type": "Non covid vaccine", "pharmacological_treatment": "Non covid vaccine"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}, {"arm_notes": "no third arm to delete", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
June 17, 2022, 12:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Immunotherapy; Active;Administration; Sublingual;Administration; Intranasal;Nasal Sprays;CIGB 2020;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.Group II (control): Treatment established in the national action protocol for COVID-19.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (control): Treatment established in the national action protocol for COVID-19.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 285, "treatment_name": "Cigb 2020", "treatment_type": "Non covid vaccine", "pharmacological_treatment": "Non covid vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]
March 17, 2022, 5 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.Group II (control): Treatment established in the national action protocol for COVID-19.;Immunotherapy; Active;Administration; Sublingual;Administration; Intranasal;Nasal Sprays;CIGB 2020", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (control): Treatment established in the national action protocol for COVID-19.;Immunotherapy; Active;Administration; Sublingual;Administration; Intranasal;Nasal Sprays;CIGB 2020", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 285, "treatment_name": "Cigb 2020", "treatment_type": "Non covid vaccine", "pharmacological_treatment": "Non covid vaccine"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
March 11, 2022, 3:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Immunotherapy; Active;CIGB 2020;Nasal Sprays;Administration; Intranasal;Administration; Sublingual;Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.Group II (control): Treatment established in the national action protocol for COVID-19.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (control): Treatment established in the national action protocol for COVID-19.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "(100 \u00b5g nasal spray;2;days1-7)+(100 \u00b5g/1ML sublingual daily)", "treatment_id": 285, "treatment_name": "Cigb 2020", "treatment_type": "Non covid vaccine", "pharmacological_treatment": "Non covid vaccine"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
May 27, 2021, 12:45 a.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.Group II (control): Treatment established in the national action protocol for COVID-19.;Nasal Sprays;Immunotherapy; Active;Administration; Sublingual;Administration; Intranasal;CIGB 2020", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 \u00b5g HBsAg + 100 \u00b5g HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (control): Treatment established in the national action protocol for COVID-19.;Nasal Sprays;Immunotherapy; Active;Administration; Sublingual;Administration; Intranasal;CIGB 2020", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]
March 26, 2021, 2:21 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 ug HBsAg + 100 ug HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19. Group II (control): Treatment established in the national action protocol for COVID-19.;Immunotherapy; Active;CIGB 2020", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I (experimental): Treatment with CIGB 2020 nasal spray: on days 1 and 7 and sublingual CIGB2020: daily during 7 days. The dose for both routes of administration (100 ug HBsAg + 100 ug HBcAg / 1 mL /) + Treatment established in the national action protocol for COVID-19.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (control): Treatment established in the national action protocol for COVID-19.;Immunotherapy; Active;CIGB 2020", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]